1d
DelveInsight's "LUXTURNA Market Size, Forecast, and Market Insight Report" highlights the details around LUXTURNA, a one-time ...
In a groundbreaking advancement for families grappling with the challenges of Dravet syndrome, a rare and life-altering form ...
Bharat Biotech aims to democratize gene therapies, traditionally considered prohibitively expensive and available primarily ...
LUXTURNA has significant market potential due to the high unmet need for effective treatments in rare genetic conditions. With its FDA approval for specific mutations in the RPE65 gene, it offers ...
OXB honoured at 2025 CDMO Leadership Awards in 'Cell & Gene Therapy – Global' category Oxford, UK – 21 March 2025: OXB (LSE: ...
Scientists developed a promising gene replacement therapy for Dravet syndrome in mice. The therapy alleviated symptoms ...
The first-of-its-kind facility in India has received an investment of $75 million from the company to build it vertically ...
Asian News International on MSN7d
Bharat Biotech launches India's only integrated cell, gene therapy, and viral production facilityBharat Biotech International Limited (BBIL), a pioneer in affordable indigenous vaccine development and manufacturing, ...
Sarepta Therapeutics said on Tuesday a young man has died due to acute liver failure after treatment with its gene therapy for a rare muscular dystrophy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback